Medicine & Health

Washington University School of Medicine is joining the National Institutes of Health (NIH)’s Bridge2AI program, an estimated $130 million initiative. One project aims to develop a framework for using artificial intelligence to diagnose disease based on the sound of patients’ voices.

Using Fitbits and a novel machine learning model, a multi-institutional team led by Washington University’s Chenyang Lu is ushering in the next step in personalization for treatment of depression.

Fred Ssewamala, the William E. Gordon Distinguished Professor at the Brown School, received a five-year $3.2 million grant from the National Institutes of Health to lead a study on intervention strategies for HIV treatments among Ugandan youth. The study could advance intervention science for HIV care globally.

Research from Ryan Bogdan’s BRAIN Lab in Arts & Sciences finds signs of psychopathology persist into mid-adolescence in kids exposed to cannabis in the womb.

To develop guidelines to evaluate artificial intelligence (AI) in nuclear-medicine imaging, an interdisciplinary team established by Richard L. Wahl, MD, director of Mallinckrodt Institute of Radiology (MIR) and led by Abhinav Jha, assistant professor at the McKelvey School of Engineering, published Recommendations for Evaluation of AI for Nuclear Medicine in the Journal of Nuclear Medicine.

Researchers led by the McKelvey School of Engineering’s Hong Chen recently invented a technique for generating ultrasound waves that can self-bend, like a rainbow.

The world’s first nasal vaccine for COVID-19 was approved Sept. 6 in India for emergency use. The vaccine, called iNCOVACC, is based on technology licensed from Washington University and developed in collaboration with Bharat Biotech International Limited in India.

Ismael Seáñez received a five-year $1 million grant from the National Institutes of Health (NIH) to lead interdisciplinary spinal cord injury research.

Men with low testosterone who develop COVID-19 are at elevated risk of becoming seriously ill and ending up in the hospital, according to a study by researchers at Washington University School of Medicine and Saint Louis University School of Medicine.

A new study from Washington University School of Medicine suggests a simple blood test — administered before CAR-T cell treatment is initiated — may identify which patients are predisposed to developing neurotoxic side effects after CAR-T cell therapy, which is used to treat several cancers.